KAIROS PHARMA, LTD. Basic Shares Outstanding (Weighted Average)
KAIROS PHARMA, LTD. (KAPA) reported Basic Shares Outstanding (Weighted Average) of 21.42 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-12
- KAIROS PHARMA, LTD. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 21.42M shares, a 24.44% increase year-over-year.
- KAIROS PHARMA, LTD. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 21.01M shares, a 32.34% increase year-over-year.
- KAIROS PHARMA, LTD. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 20.85M shares, a 55.74% increase year-over-year.
- KAIROS PHARMA, LTD. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 20.21M shares, a 85.20% increase year-over-year.
- KAIROS PHARMA, LTD. weighted average number of shares outstanding, basic for fiscal 2025 was 18.43M shares, a 62.27% increase from fiscal 2024.
- KAIROS PHARMA, LTD. weighted average number of shares outstanding, basic for fiscal 2024 was 11.36M shares, a 9.38% increase from fiscal 2023.
- KAIROS PHARMA, LTD. weighted average number of shares outstanding, basic for fiscal 2023 was 10.38M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 21.42M shares 10-Q · filed 2026-08-12 | 21.21M shares 10-Q · filed 2026-08-12 | 21.09M shares derived: average of 3 quarters · filed 2026-08-12 | 20.87M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | 21.01M shares 10-Q · filed 2026-05-13 | 20.93M shares derived: average of 2 quarters · filed 2026-05-13 | 20.69M shares derived: average of 3 quarters · filed 2026-05-13 | 19.82M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | 20.85M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | 20.53M shares derived: average of 2 quarters · filed 2026-03-31 | 19.42M shares derived: average of 3 quarters · filed 2026-08-12 | 18.43M shares 10-K · filed 2026-03-31 |
| 2025-09-30 | 20.21M shares 10-Q · filed 2025-11-14 | 18.71M shares derived: average of 2 quarters · filed 2026-08-12 | 17.62M shares 10-Q · filed 2025-11-14 | 16.67M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | 17.21M shares 10-Q · filed 2026-08-12 | 16.31M shares 10-Q · filed 2026-08-12 | 15.49M shares derived: average of 3 quarters · filed 2026-08-12 | 14.35M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | 15.88M shares 10-Q · filed 2026-05-13 | 14.63M shares derived: average of 2 quarters · filed 2026-05-13 | 13.39M shares derived: average of 3 quarters · filed 2026-05-13 | 12.68M shares derived: average of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | 13.39M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | 12.15M shares derived: average of 2 quarters · filed 2026-03-31 | 11.62M shares derived: average of 3 quarters · filed 2026-03-31 | 11.36M shares 10-K · filed 2026-03-31 |
| 2024-09-30 | 10.91M shares 10-Q · filed 2025-11-14 | 10.74M shares derived: average of 2 quarters · filed 2025-11-14 | 10.68M shares 10-Q · filed 2025-11-14 | 10.64M shares derived: average of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | 10.56M shares 10-Q · filed 2025-08-12 | 10.56M shares 10-Q · filed 2025-08-12 | 10.55M shares derived: average of 3 quarters · filed 2025-08-12 | 10.50M shares derived: average of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | 10.56M shares 10-Q · filed 2025-05-14 | 10.54M shares derived: average of 2 quarters · filed 2025-05-14 | 10.47M shares derived: average of 3 quarters · filed 2025-05-14 | |
| 2023-12-31 | 10.53M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | 10.43M shares derived: average of 2 quarters · filed 2025-04-15 | 10.38M shares 10-K · filed 2025-04-15 | |
| 2023-09-30 | 10.33M shares 10-Q · filed 2024-11-14 | 10.33M shares 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |